MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/icvts/ivag137

Медицинская библиотека · Interdisciplinary cardiovascular and thoracic surgery · 2026

Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.

Martínez-Comendador José Manuel, Martín Gutiérrez Elio, Ortiz Berbel Daniel, Alcalde Lucía García, Pedraz Prieto Álvaro, Muñoz-Guijosa Christian, Martín López Carlos Esteban, Urso Stefano, Rábago Juan Aracil Gregorio, Cuenca Castillo José Joaquín, Pérez-Guillén Manuel

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

Impella 5.5 is an established temporary mechanical circulatory support (tMCS) device for severe cardiogenic shock. Spain, characterized by high heart transplant activity and increasing use of controlled donation after circulatory death (DCD), provides a relevant setting to evaluate its use and outcomes. We aimed to describe clinical characteristics, trajectories, and outcomes of Impella 5.5 support in the first Spanish multicentre cohort from heart transplant centres.

METHODS

Retrospective multicentre observational study including consecutive patients supported with Impella 5.5 in hospitals with active heart transplant programmes. Baseline characteristics, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, additional support, complications, support duration, and in-hospital mortality were recorded. Outcomes were analysed across INTERMACS profiles.

RESULTS

Ninety-three patients were included (33 INTERMACS 1, 37 INTERMACS 2, 23 INTERMACS 3). Additional support was required in 46%, mainly venoarterial extracorporeal life support (VA-ECLS). Device-related complications were reported as event frequencies. The predominant clinical trajectory was heart transplantation (68.8%), contrasting with international series in which long-term mechanical support and transplantation are more evenly distributed. In-hospital mortality was 43%, with a clear gradient across INTERMACS profiles 1-3 (60.6%, 37.8%, and 26.1%, respectively; P = .013). Mean support duration was 16 days, and more than one-third of transplants were from controlled DCD donors.

CONCLUSIONS

Impella 5.5 was used as tMCS in severe cardiogenic shock and was predominantly associated with heart transplantation in a transplant-oriented healthcare system. Outcomes were closely associated with INTERMACS profile, reflecting differences in baseline severity and patient selection. Comparisons with international registries are descriptive only.

Для цитирования: Martínez-Comendador José Manuel, Martín Gutiérrez Elio, Ortiz Berbel Daniel, Alcalde Lucía García, Pedraz Prieto Álvaro, Muñoz-Guijosa Christian, Martín López Carlos Esteban, Urso Stefano, Rábago Juan Aracil Gregorio, Cuenca Castillo José Joaquín, Pérez-Guillén Manuel. Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres.. Interdisciplinary cardiovascular and thoracic surgery. 2026. DOI: 10.1093/icvts/ivag137.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.